MedPath

Midas Pharma Gmbh

Midas Pharma Gmbh logo
🇸🇪Sweden
Ownership
Private
Established
1988-01-01
Employees
251
Market Cap
-
Website
http://www.midas-pharma.com

Clinical Trials

2

Active:0
Completed:2

Trial Phases

1 Phases

Phase 1:2

Drug Approvals

4

EMA:2
CIMA_AEMPS:2

Drug Approvals

Epruvy (previously Ranibizumab Midas)

Authorization Status
Authorised
Approval Date
Sep 19, 2024
EMA

Ranivisio

Authorization Status
Authorised
Approval Date
Aug 25, 2022
EMA

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (100.0%)

Drug-drug-interaction Study of Ramipril, Amlodipine and Atorvastatin

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Ramipril, Amlodipine and Atorvastatin
First Posted Date
2020-02-10
Last Posted Date
2020-02-10
Lead Sponsor
Midas Pharma GmbH
Target Recruit Count
18
Registration Number
NCT04262765
Locations
🇯🇴

International Pharmaceutical Research Center, Amman, Jordan

Drug-drug-interaction Study of Candesartan, Amlodipine and Atorvastatin

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2020-01-28
Last Posted Date
2020-02-05
Lead Sponsor
Midas Pharma GmbH
Target Recruit Count
18
Registration Number
NCT04245046
Locations
🇯🇴

International Pharmaceutical Research Center, Amman, Jordan

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.